It's healthy to talk about health
Many of us don't want to talk about our physical and mental health. But new research suggests that doing so can actually have a positive impact on our wellbeing.
Bupa, the international healthcare company, is encouraging all of us to talk about our health through a new global campaign, Health Stories , which launches today.
The company has created a suite of films featuring people sharing their experiences of a wide range of health conditions. By capturing these incredible voices, Bupa is breaking down the barriers of stigma and embarrassment, while also tackling the sense of isolation that individuals too often feel as they cope with a cancer diagnosis or begin therapy for a mental health condition. It's all about removing the taboos that still affect us as a society when it comes to our health.
One story within the new film series sees a brave woman sharing her response when she was first diagnosed with breast cancer. Her immediate reaction was: this cannot be happening to me. Imagine how many have felt that same emotion but kept it to themselves? Another person shares their experience of being a deaf person with ADHD, which is a condition he believes has never been discussed in public before. And an amputee explains how she was able to start enjoying life again after she expressed her feelings to her prosthetist who listened and understood.
Dr Mohamed Maan, Head of Clinical Operations, Bupa Global explains why this campaign can have a positive impact:
'Hearing how another person has managed a health condition can make you feel so many things—connected, empowered, supported, hopeful, a sense of relief.'
Ruby Tui, 2021 Rugby World Cup champion and a mental heath advocate.
New research from Bupa shows that while four in five people believe that sharing their health stories can support physical and mental health, almost half (49 percent) have avoided addressing a health concern. Yet of those who have avoided a health concern, over half (53 percent) admitted that it caused them more worry, and over a third (31 percent) felt their health worsened. The overall picture is that people really do want to talk—they just need the means and encouragement to do it.
Ruby Tui is a New Zealand rugby union player who has competed internationally, won gold at the 2020 Olympics, and was a member of the Black Ferns team that triumphed in the 2021 Rugby World Cup. Through openly sharing her mental health story, she advocates for others to do the same so they can get the support and help they need:
'Through the simple task of sharing, we can open ourselves up to different perspectives, and we can empower ourselves to find solutions. I hope this campaign from Bupa sheds light on the importance of our individual health and wellness journeys and inspires more people to make their health a priority that they talk about openly and honestly.'
Junior who has Crohn's disease
Bupa's ambition with Health Stories is to encourage people to proactively seek the care they might need—inspired by the stories they have watched. As a result of these conversations and moving testimonies, we can all realize that there are millions of us, every day, with a health condition that doesn't need to be endured alone. A simple conversation can make a big difference.
For more inspiring real-life health stories, visit Bupa.com/healthstories.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Natera initiates trial of Signatera test for breast cancer
Natera has announced the initiation of the Phase II TEODOR trial of its Signatera test aimed at replacing chemotherapy with endocrine therapy before surgery in certain breast cancer patients. The multicentre, randomised controlled trial (RCT) focuses on women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer who are responsive to endocrine treatment and test negative with Signatera. Academic research organisation Austrian Breast & Colorectal Cancer Study Group sponsored the trial, which plans to enrol 250 subjects across 15 Austrian sites. This trial seeks to assess the endocrine therapy's efficacy in comparison to chemotherapy in those who are Signatera-negative, to minimise the use of pre-operative chemotherapy and its associated side effects. After receiving an endocrine therapy course for four weeks, subjects who remain Signatera-negative and exhibit a favourable response as per the Ki-67 proliferation index measurement are set to be randomised to continue with endocrine therapy or chemotherapy. The primary goal of the TEODOR trial is the response rate to neoadjuvant therapy, gauged by pathological complete response (pCR) and modified Preoperative Endocrine Prognostic Index (PEPI) score, across endocrine and chemotherapy trial arms. Secondary goals encompass long-term effects such as recurrence of breast cancer and overall survival rates. Signatera is a custom-built blood test for identifying molecular residual disease (MRD) in the form of circulating tumour DNA. Natera oncology medical director Angel Rodriguez said: 'With the TEODOR trial, our goal is to identify patients who may be able to safely forgo chemotherapy. 'We are proud to collaborate with ABCSG on this important trial, and we hope this study will support the role of Signatera in guiding neoadjuvant therapy in breast cancer.' The test is covered by Medicare for those with stage IIb and higher breast cancer. In May 2025, Natera announced outcomes from a study assessing the Signatera MRD test in those with soft tissue and bone sarcomas. "Natera initiates trial of Signatera test for breast cancer" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Fox News
2 hours ago
- Fox News
Common sweetener could hold untapped potential to fight aggressive cancer, study finds
A household sweetener could hold the potential to create an anti-cancer treatment. New research from Hiroshima University in Japan revealed that stevia leaf extract could help fight pancreatic cancer cells. The leaves of the stevia plant (Stevia rebaudiana) are used to make stevia extract, a naturally sweet substance commonly used as a sugar substitute. The study, published in the International Journal of Molecular Sciences, investigated the anti-cancer properties of stevia leaf extract when it is fermented with a certain strain of bacteria. In laboratory research, the fermented extract exhibited "significantly enhanced antioxidant activity and cytotoxicity" against pancreatic cancer cells, the researchers revealed. This led them to believe that this substance could serve as a "promising candidate for pancreatic cancer treatment." Paul E. Oberstein, M.D., medical oncologist and assistant director of the Pancreatic Cancer Center at NYU Langone Perlmutter Cancer Center, shared his thoughts in an interview with Fox News Digital. "This is an interesting study because it evaluated something derived from a natural plant (stevia) and showed that it may have utility in stopping cancer cells from growing in the laboratory," he said. "As the authors point out, the actual stevia plant does not seem to have any benefit for stopping cancer, so they had to use a chemical process to change the plant and make it stronger with a fermentation process." "This is the process of how we discover new treatments – some of which turn out to be absolute game-changers." Oberstein recommended approaching this with caution, as it is unknown whether altering the plant will lead to side effects or toxicity. The study was not performed on humans, so there is "still a lot that's unknown about whether this will help patients," the oncologist added. As stevia extract alone does not have an impact on cancer cells, Oberstein said these findings most likely will not lead to any immediate changes in treatment plans. "The study suggests that if the stevia can be changed in the lab, it may have an impact, so hopefully they will further test this and determine whether this effect happens when tested in people and if it doesn't cause new side effects," he added. "I hope the researchers keep testing this in various formats and in people." Dr. Kristen Arnold, a surgical oncologist and pancreatic cancer specialist at the Orlando Health Cancer Institute, reacted to these study findings in a separate interview with Fox News Digital. "Pancreatic cancer is a very aggressive malignancy," she said. "And we know that even with the most aggressive of therapies, unfortunately, our outcomes are not good." "As a pancreatic cancer community, we spend a lot of time and there's a lot of ongoing effort into trying to find better modalities to treat this disease." Although more research is needed to confirm these preliminary findings, Arnold said she is encouraged by the study. "I think the data's very early to know if it's ultimately going to be a game-changer, but it's very exciting to know that we're finding some positive pre-clinical data," she said. "This is the process of how we discover new treatments – some of which turn out to be absolute game-changers and make dramatic changes in the lives of our patients." "Not all of it pans out, but it's a process of discovery," Arnold added. For those with pancreatic cancer, Arnold recommends seeking out appropriate clinical trial opportunities as new science develops. "The clinical trials are ultimately what determine how we treat patients on a day-to-day basis," she added. Fox News Digital reached out to the study authors for comment.
Yahoo
3 hours ago
- Yahoo
Millions on NHS waiting lists yet to have first appointment
Millions of people in England on NHS waiting lists are yet to have their first appointment, new data reveal. Figures from NHS England last month suggest nearly half of those waiting for hospital care have not had their first appointment with a specialist or a diagnostic test since their GP referral. An analysis by health data specialist MBI Health suggests nearly three million out of the 6.23 million patients (48 per cent) waiting for treatment are left in limbo. Experts referred to the issue as a 'frontlog' and warned the crisis 'has gone unchallenged for too long'. MBI's analysis also found that around 70 per cent of referral-to-treatment pathways fall into the category of being 'unseen' since the patient's GP referred them to a specialist. Delays in making a first assessment can lead to late diagnosis, worsening symptoms and pressure on emergency services. The analysis found that ear, nose and throat, trauma and orthopaedics, gastroenterology, ophthalmology and gynaecology and obstetrics departments were consistently the specialist departments with the greatest number of patients not seen for the first time. 'That's a breakdown' As part of the Government's 10-year health plan, the NHS is expected to meet its target of carrying out 92 per cent of routine operations and appointments within 18 weeks by March 2029 – a target that has not been achieved for almost a decade. The latest figures show how challenging that target will be given an estimated one million of the three million unseen patients have already gone more than 18 weeks without receiving any care. 'If accurate, three million people are trapped in an invisible waiting-list crisis, stuck without basic diagnostic tests of first appointments while their conditions worsen,' Rachel Power, the chief executive of the Patients Association, told the Guardian. 'The scale is staggering, as nearly half of all patients on a waiting list haven't been seen by anyone. That's not a healthcare service; that's a breakdown. 'These aren't just statistics. They're people checking their phones daily for hospital calls that never come, unable to plan their lives while their symptoms deteriorate.' Last month it was found people of working age are making up a growing proportion of those on the NHS waiting list for treatment in England. Data tables published for the first time by NHS England also show people in the most deprived parts of the country are more likely to wait more than a year to start hospital treatment than those in the least deprived. The figures, analysed by the PA news agency, showed 56.1 per cent of those on the list at the end of June this year were of working age (defined as age 19 to 64), up from 55.8 per cent a year ago and 55 per cent in June 2022. At the same time, the proportion of people on the waiting list under the age of 19 has fallen, standing at 10.8 per cent in June this year, down from 11.2 per cent a year earlier and 11.9 per cent in June 2022. The proportion who are over 65 has remained broadly unchanged at around 33.1 per cent. People of working age are also more likely to have to wait more than a year to start treatment (three per cent of patients in this age group at the end of June) than those over 65 (two and half per cent). However, the proportion is the same as those under 19 (also three per cent). An NHS spokesman said: 'NHS staff have made significant progress in reducing waiting lists in the last year, which are down by more than 260,000 since June 2024. 'All patients are assessed by clinicians as they are added to waiting lists, and we will continue with our plan to improve waiting times for patients throughout the year.' Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more. Solve the daily Crossword
